Biosimilars in Inflammatory bowel disease, challenges and opportunities

Aims & Scope:

The first monoclonal blicking TNF has been recently approved in 2013, and biosimilars represent a key opportunity for doctors caring for inflammatory bowel disease. Multiple issues are still controversial and deserve full attention. Aim of the issue is to review the state of the art of biosimilars in inflammatory bowel disease.

Keywords: Biosimilars, inflammatory bowel disease.

Subtopics:

1. Introduction: Biosimilars, challenges and opportunities
2. Biosimilars and originators: similarities and differences
3. Biosimilars in IMID: efficacy and safety
4. Biosimilars in IBD: efficacy, safety and immunogenicity
5. The regulatory process of biosimilars
6. Patient’s profile for biosimilars in IBD
7. Can we extrapolate data from one IMID to another one?
8. The problem of naming: which name for which biologic?
9. Cost issues with biosimilars: what can be expected?